The report "Blood Screening Market by Technology
(Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid
Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits,
Software) & End User (Blood Bank, Hospital) - Global Forecasts to 2021"The global blood screening market is expected to reach USD 2.80 Billion
by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7% from 2016 to 2021
Browse 97 market data tables and
39 figures spread through 150 pages and in-depth TOC on “Blood Screening
Market”
Early buyers will receive 10% customization on this
report.
The major factors driving the growth of this market are
increasing number of blood donations and blood donors, growing affordability
and adoption of nucleic acid amplification test (NAT) for blood screening,
rising awareness regarding the safety of donated blood, growing demand for
donated blood, and increasing prevalence/incidence of infectious diseases.
Blood screening is a medical process in which donated blood
is mainly tested for HIV1, HIV2, HBV, HCV, malaria, syphilis, and various other
infectious diseases. Donated blood is screened for these infectious diseases to
reduce the risk of transfusion-transmitted infections (TTIs).
This report segments the blood screening market on the basis
of technology, product & service,
end user, and region
Based on technology,
the market is segmented into NAT, ELISA, rapid tests, western blot assays, and
NGS. The NAT segment is further sub segmented into TMA and real-time PCR. The
ELISA technology segment is further categorized into various generations and
platforms. On the basis of generation, the ELISA segment is further divided
into first generation ELISA, second generation ELISA, third generation ELISA,
and fourth & above generation ELISA.
On the basis of product
and service, the blood screening market is segmented into reagents &
kits, instruments, and software & services. The reagents & kits segment
is further sub segmented into NAT, ELISA, and other reagents and kits. The
instrument segment is categorized based on purchase mode and is further sub
segmented into rental purchase and outright purchase.
Get The PDF Brochure For This Report@
On the basis of end user, the blood screening market is segmented into blood banks
and hospitals. The blood banks segment is expected to account for the largest
share of the market in 2016. Major factors driving the growth of this segment
are the increasing demand for donated blood, growing number of organ
transplantation surgeries, rising awareness regarding the safety of blood,
increasing number of donations worldwide, and growth in government funding to
charitable trusts.
On the basis of region, the blood screening market is segmented into North America,
Europe, Asia, and the Rest of the World (RoW). North America is expected to
account for the largest share of the market in 2016. Growth in this regional
segment is driven by factors such as increasing adoption of nucleic acid tests
(NAT) and increasing participation of various government associations in blood
donations and screening & transfusion activities.
Key players in the blood screening
market include Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche
Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc.
(U.S.), Siemens Healthineers (Germany), Abbott Laboratories (U.S.), Ortho
Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), and
Beckman Coulter, Inc. (U.S.).
About MarketsandMarkets™:
MarketsandMarkets™
provides quantified B2B research on 30,000 high growth niche opportunities/threats
which will impact 70% to 80% of worldwide companies’ revenues. Currently
servicing 5000 customers worldwide including 80% of global Fortune 1000
companies as clients. Almost 75,000 top officers across eight industries
worldwide approach MarketsandMarkets™ for their painpoints around revenues
decisions.
Our 850 fulltime
analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets
following the "Growth Engagement Model – GEM". The GEM aims at
proactive collaboration with the clients to identify new opportunities,
identify most important customers, write "Attack, avoid and defend"
strategies, identify sources of incremental revenues for both the company and
its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this
year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets’s
flagship competitive intelligence and market research platform, "RT"
connects over 200,000 markets and entire value chains for deeper understanding
of the unmet insights along with market sizing and forecasts of niche
markets.
Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441
No comments:
Post a Comment